VivoPower stock soars on Kweather partnership for XRP exposure

Investing.com -- IceCure Medical Ltd (NASDAQ:ICCM) stock jumped 3.9% in premarket trading Monday following the publication of a study showing improved survival rates for lung cancer patients treated with the company’s cryoablation technology.

The independent study, published in the peer-reviewed journal PLOS One, demonstrated that combining stereotactic body radiation therapy (SBRT) with IceCure’s cryoablation system achieved a 74% five-year overall survival rate for stage I non-small cell lung cancer patients. This compares favorably to published studies reporting 41-52% five-year survival rates with SBRT alone.

The research, led by Dr. Hiroaki Nomori of Kashiwa Kousei General Hospital in Japan, evaluated 64 patients with tumors averaging 2.7 cm in diameter. Results showed a 93% five-year local control rate and 92% five-year disease-specific survival rate, with no treatment-related mortality.

"While radiation therapy is the standard of care for inoperable stage I NSCLC patients, using SBRT alone unfortunately results in far lower overall survival and lower local control than surgery in certain patients," said Eyal Shamir, IceCure’s CEO. "This study provides very encouraging results confirming that combining SBRT with our cryoablation system offers inoperable patients longer life expectancy."

The study’s outcomes approach those of surgical intervention, which has reported five-year overall survival rates of 67-82% according to published studies.

IceCure’s minimally-invasive technology destroys tumors by freezing them as an alternative to surgical removal. The company noted that lung cancer remains the most frequently diagnosed cancer worldwide with 2.5 million cases annually and is the leading cause of cancer-related deaths.

This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.

Investing.com -- Apple’s iPhone 17 base model remains the standout performer in the company’s latest smartphone lineup, according to Jefferies analysts, who said it “continues to show the most consistent strength” across major markets.

“Our tracking shows no delivery lead time for 17 Air/17 Pro in all six markets that we track, same as the previous week,” Jefferies analyst Edison Lee wrote. 

“The base model continues to show the most consistent strength, as HK saw a big WoW fall, but the U.S. showed a rise of 13 days, and the rest saw no drop.”

Jefferies stated that overall demand remains strongest for the iPhone 17 base model and, to a lesser extent, the 17 Pro Max. 

The brokerage added that Apple “may have cut the order for 17 Air by 4 million (from 10 million to 6 million), but raised the orders for the other models by 10 million,” reflecting stronger demand for higher-end versions.

Lee noted that in Hong Kong, only the 512GB variants of the 17 Pro Max “still trade at a small premium (0.4% to 2%), indicating reasonably strong demand.” 

That’s “much stronger than last year, when all variants of 16 Pro Max began trading at discounts as of the third week of launch,” the analyst added.

Jefferies attributed the robust demand partly to “no price hikes for Pro/Pro Max for three years despite ongoing hardware improvements,” as well as “the introduction of a brand new color orange, which appeals to young female consumers.”

While Apple guided for 10% to 12% revenue growth in the December quarter, Jefferies warned that the “unfavorable product mix on 17 vs. 16 could translate into margin pressure.”

Investing.com -- Amazon (NASDAQ:AMZN) stock rose 5.4% Monday after the company’s cloud division AWS announced a multi-year strategic partnership with OpenAI valued at $38 billion.

The agreement will enable OpenAI to run its advanced AI workloads on AWS’s infrastructure starting immediately. Under the terms of the deal, which will grow over the next seven years, OpenAI will access AWS compute power comprising hundreds of thousands of NVIDIA GPUs, with the ability to expand to tens of millions of CPUs to scale AI operations.

AWS will provide OpenAI with Amazon EC2 UltraServers featuring both GB200 and GB300 NVIDIA chips in a sophisticated architectural design optimized for AI processing efficiency. The infrastructure is designed to support various workloads, from serving inference for ChatGPT to training next-generation models.

"Scaling frontier AI requires massive, reliable compute," said OpenAI co-founder and CEO Sam Altman. "Our partnership with AWS strengthens the broad compute ecosystem that will power this next era and bring advanced AI to everyone."

The partnership builds on the companies’ existing collaboration. Earlier this year, OpenAI’s open weight foundation models became available on Amazon Bedrock, bringing additional model options to AWS customers. According to the announcement, OpenAI has quickly become one of the most popular model providers on Amazon Bedrock, with thousands of customers using their models.

All capacity under the new agreement is targeted to be deployed before the end of 2026, with the ability to expand further into 2027 and beyond.